Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples